• Drug: Adempas (riociguat)
  • Manufacturer: Bayer
  • Route of Administration: Oral
  • Site of Care: Outpatient

  • Approved Indication:

    • persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and functional class
    • pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, improve functional class, and delay clinical worsening
  • Disease: chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension
  • Therapeutic Area: Pulmonary
  • Enrollment Form Link: www.adempashcp.com/forms
  • Phone Number: 1-855-423-3672
  • Fax Number: 1-855-662-5200

  • Product Website: